经皮冠状动脉介入治疗的抗凝治疗 - Suppr

Suppr

超能文献

Anticoagulant therapy for percutaneous coronary intervention.

作者信息

Rao Sunil V, Ohman E Magnus

机构信息

Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA.

出版信息

Circ Cardiovasc Interv. 2010 Feb 1;3(1):80-8. doi: 10.1161/CIRCINTERVENTIONS.109.884478.

DOI:10.1161/CIRCINTERVENTIONS.109.884478

PMID:20160186

Abstract

摘要

相似文献

Anticoagulant therapy for percutaneous coronary intervention.经皮冠状动脉介入治疗的抗凝治疗

Circ Cardiovasc Interv. 2010 Feb 1;3(1):80-8. doi: 10.1161/CIRCINTERVENTIONS.109.884478.

Clinical pharmacology of bivalirudin.比伐卢定的临床药理学。

Pharmacotherapy. 2002 Jun;22(6 Pt 2):105S-111S. doi: 10.1592/phco.22.10.105s.33616.

Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?用于直接经皮冠状动脉介入治疗的抗凝剂——普通肝素的最后一曲？

Arch Cardiovasc Dis. 2012 May;105(5):259-61. doi: 10.1016/j.acvd.2012.03.002. Epub 2012 May 22.

The role of bivalirudin in percutaneous coronary intervention.

J Invasive Cardiol. 2000 Dec;12 Suppl F:1F.

The role of thrombin inhibition during percutaneous coronary intervention.经皮冠状动脉介入治疗期间凝血酶抑制的作用。

Pharmacotherapy. 2002 Jun;22(6 Pt 2):97S-104S. doi: 10.1592/phco.22.10.97s.33614.

A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.一项评估抗血小板和抗血栓药物对经皮冠状动脉介入术后微血管功能障碍、缺血及炎症相对保护作用的随机试验：PROTECT-TIMI-30试验

J Am Coll Cardiol. 2006 Jun 20;47(12):2364-73. doi: 10.1016/j.jacc.2005.12.077.

Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.急性冠状动脉综合征患者的经皮冠状动脉介入治疗：聚焦比伐卢定

Vasc Health Risk Manag. 2008;4(3):493-505. doi: 10.2147/vhrm.s2455.

Direct thrombin inhibitors (part 1 of 2).

J Invasive Cardiol. 2005 Jan;17(1):34-8.

Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.比伐卢定用于肝素诱导的血小板减少症患者经皮冠状动脉介入治疗

J Invasive Cardiol. 2000 Dec;12 Suppl F:14F-9.

Debate of adjunctive pharmacology for percutaneous coronary intervention: thrombin inhibitors and clopidogrel are enough.经皮冠状动脉介入治疗辅助药理学的争论：凝血酶抑制剂和氯吡格雷就足够了。

J Interv Cardiol. 2006 Oct;19(5):464-9. doi: 10.1111/j.1540-8183.2006.00180.x.

引用本文的文献

Percutaneous Coronary Intervention with Procedural Unfractionated Heparin without Activated Clotting Time Guidance: A Unique Opportunity to Assess Thrombotic and Bleeding Events.经皮冠状动脉介入治疗中不使用活化凝血时间指导的普通肝素：评估血栓形成和出血事件的独特机会。

Int J Clin Pract. 2024 Feb 15;2024:6219301. doi: 10.1155/2024/6219301. eCollection 2024.

Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome.优化抗栓治疗以减轻急性冠状动脉综合征患者心血管缺血事件负担的当前及未来见解

J Clin Med. 2022 Sep 23;11(19):5605. doi: 10.3390/jcm11195605.

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.缺血事件在接受经皮冠状动脉介入治疗的患者中发生较早，并可通过坎格瑞洛减少：来自 CHAMPION PHOENIX 的研究结果。

Circ Cardiovasc Interv. 2022 Jan;15(1):e010390. doi: 10.1161/CIRCINTERVENTIONS.120.010390. Epub 2021 Dec 17.

Bivalirudin as a Systemic Anticoagulant and Flush Solution Additive for Sequential Mitral and Tricuspid Valve Percutaneous Edge-to-Edge Repair in a Patient With Heparin-Induced Thrombocytopenia.比伐卢定作为全身性抗凝剂和冲洗液添加剂，用于伴有肝素诱导血小板减少症的患者的二尖瓣和三尖瓣经皮缘对缘修复术。

J Cardiothorac Vasc Anesth. 2022 Jun;36(6):1709-1714. doi: 10.1053/j.jvca.2021.03.004. Epub 2021 Mar 6.

New Antithrombotic Drugs in Acute Coronary Syndrome.急性冠状动脉综合征中的新型抗血栓药物

J Clin Med. 2020 Jun 30;9(7):2059. doi: 10.3390/jcm9072059.

Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials.比伐卢定与普通肝素在急性冠状动脉综合征介入治疗中的比较：一项随机试验的系统评价。

Cardiovasc Hematol Disord Drug Targets. 2020;20(1):3-15. doi: 10.2174/1871529X19666190626124057.

Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study).依诺肝素 6 小时疗程对行经皮冠状动脉介入治疗（PENNY PCI 研究）的患者的药效学影响。

Thromb Haemost. 2018 Jul;118(7):1250-1256. doi: 10.1055/s-0038-1657768. Epub 2018 Jun 6.

Update on pharmacological treatment of acute coronary syndrome without persistent ST segment elevation myocardial infarction in the elderly.老年非持续性ST段抬高型心肌梗死急性冠状动脉综合征的药物治疗进展

J Geriatr Cardiol. 2017 Jul;14(7):457-464. doi: 10.11909/j.issn.1671-5411.2017.07.005.

Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE).急性冠状动脉综合征（ACS）患者抗栓治疗的临床路径与管理：来自意大利医院心脏病学家协会（ANMCO）、意大利心脏病学会（SIC）、意大利急诊医学学会（SIMEU）和意大利介入心脏病学会（SICI - GIS）的共识文件

Eur Heart J Suppl. 2017 May;19(Suppl D):D130-D150. doi: 10.1093/eurheartj/sux013. Epub 2017 May 2.

Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban.抗凝治疗中未满足的需求：利伐沙班的潜在作用。

Cardiol Res. 2015 Jun;6(3):267-277. doi: 10.14740/cr413w. Epub 2015 Jun 11.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验